Current Lyme disease tests look for antibodies produced by the immune system in response to Borrelia burgdorferi bacteria transmitted to humans by infected blacklegged ticks. My guest today says, "The problem is that these antibodies don't have the right characteristics to be clinically useful".
New research led by Tufts University School of Medicine suggests that a group of immune molecules called anti-lipid antibodies may address these shortcomings.
Joining me today do discuss this problem and the potential solution is Peter Gwynne, Phd. Dr Gwynne is a research assistant professor at Tufts University School of Medicine and the senior author of the new paper published in the journal, Infection and Immunity.
Podden och tillhörande omslagsbild på den här sidan tillhör
Robert Herriman. Innehållet i podden är skapat av Robert Herriman och inte av,
eller tillsammans med, Poddtoppen.
